* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Genetics Overview - Alport Syndrome Foundation
Survey
Document related concepts
DNA paternity testing wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Quantitative trait locus wikipedia , lookup
Medical genetics wikipedia , lookup
Genome (book) wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Microevolution wikipedia , lookup
Tay–Sachs disease wikipedia , lookup
Population genetics wikipedia , lookup
Genealogical DNA test wikipedia , lookup
Genetic testing wikipedia , lookup
Point mutation wikipedia , lookup
Transcript
Alport Syndrome Genetics and Diagnosis Martin Gregory, MD, PhD Professor of Medicine University of Utah Nothing to disclose Modes of Inheritance • X-linked (XLAS) – COL4A5 on chromosome Xq22 85% of cases • Autosomal – COL4A3 or COL4A4 on chromosome 2q36-37 – Recessive (ARAS) 10-15% of cases – Autosomal Dominant (ADAS) 1-5% of cases • Diseases mimicking AS – MYH9 disorders: Epstein and Fechtner syndromes Giant Platelets in Fechtner Syndrome Autosomal Dominant AS • Rare, mild • Vertical pattern of inheritance • Male to male transmission • Mutation in COL4A3 or COL4A4 Autosomal Recessive AS • Uncommon • Horizontal pattern of inheritance • Consanguinity • Mutations in COL4A3 or COL4A4 • Parents are “carriers”: they have TBMN X-linked AS • Most common • Vertical pattern of inheritance • NO male to male transmission • Mutations in COL4A5 Implications of Inheritance Patterns • Need to be as sure as possible of mode of inheritance before drawing conclusions or advising families. • Prediction is treacherous, and genetic counseling subtle. • Both the chance that children will inherit the disorder and the likely severity of the syndrome vary with the type of AS Time to onset of ESRD associates with COL4A5 mutation type From the left of figure, Light weight solid line: large deletion, Dots: splice site mutation, Dash-Dot: small deletion, Heavy solid line: truncating mutation, Dash: missense mutation. Bekheirnia, M. R. et al. J Am Soc Nephrol 2010;21:876-883 Copyright ©2010 American Society of Nephrology Relevance of Specific Mutations in XLAS • Large deletions and truncations cause the most severe phenotype. • Splice-site mutations: intermediate severity • Missense mutations: relatively mild disease. • In US, but not Europe, mutations in the NC1 domain are more benign than those in the triple helical domain Genetic Tests Available – COL4A5 • Sequencing and deletion analysis – Expensive. Sensitivity > 80% for XLAS • Targeted mutation analysis (Carrier detection) – Cheap. Use this once family’s mutation is known. • Test for 3 common “Adult types” – Cheap. Use if family has one of these 3 mutations. – ?use for screening certain groups • Adults with dysmorphic hematuria and CKD. • Alport syndrome with late-onset renal failure “Adult-type” Mutations in the USA – Known gene carriers COL4A5 mutation ESRD age in males Male Female Total % of total L1649R 39 150 222 372 48.6 C1564S 32 52 81 133 17.4 R1677Q 50 19 38 57 7.5 G1170S 38 13 11 24 3.1 c.2476delC 44 11 12 23 3.0 G1234X 42 7 16 23 3.0 16 others 70 63 133 17.4 Total 322 443 765 100 Pont-Kingdon G et al. BMC Nephrology 2009; 10:38 Genetic Tests Available – COL4A3/4 • COL4A3 and COL4A4 sequencing and deletion analysis – Expensive. Sensitivity >80% • Use after COL4A5 mutation excluded or if inheritance suggests autosomal transmission • Can use to diagnose ~40% of cases of TBMN Before Genetic Testing •Gather a complete family history, patient history, u/a. •Make your best guess for mode of inheritance •Is a mutation known in the family? •Is genetic testing appropriate? •Families making reproductive decisions •To avoid kidney biopsy, or if diagnostic certainly is desired Choice of an Appropriate Genetic Test •Targeted analysis or Adult-type 3 mutation test if the mutation is known in the family •If no mutation is known, usually start with sequencing, including deletion analysis in females •May start with Adult-type 3 mutation test in families with renal failure in middle age •COL4A3/4 sequencing if autosomal disease likely or if COL4A5 testing was negative Now you Tell me … A lab test has 90% sensitivity and 99% specificity. The disease it tests for occurs in 1 in 50,000 people. A person in the population has a positive test. What is the likelihood that he has the disease tested for? 99% 90% 50% 10% <1% Now you Tell me … A lab test has 90% sensitivity and 99% specificity. The disease it tests for occurs in 1 in 50,000 people. A person in the population has a positive test. What is the likelihood that he has the disease tested for? 99% 90% 50% 10% <1% Of people with the disease 90% will have a positive test Of people without the disease, 1% will have a positive test Now you Tell me … A lab test has 90% sensitivity and 99% specificity. The disease it tests for occurs in 1 in 50,000 people. A person in the population has a positive test. What is the likelihood that he has the disease tested for? 99% 90% 50% 10% <1% Test 100,000 people 1.8 true positives Now you Tell me … Test 100,000 people A lab test has 90% sensitivity and 1.8 true positives 99% specificity. The disease it tests 1,000 false positives for occurs in 1 in 50,000 people. A person in the population has a Probability of disease positive test. What is the likelihood 2/1002 = 0.2% that he has the disease tested for? 99% 90% 50% 10% <1% Now you Tell me … Test 100,000 people A lab test has 90% sensitivity and 1.8 true positives 99% specificity. The disease it tests 1,000 false positives for occurs in 1 in 50,000 people. A person in the population has a Probability of disease positive test. What is the likelihood 2/1002 = 0.2% that he has the disease tested for? 99% 90% 50% 10% <1% A priori probability A posteriori Now you Tell me … Test 100,000 people A lab test has 90% sensitivity and 1.8 true positives 99% specificity. The disease it tests 1,000 false positives for occurs in 1 in 50,000 people. A person in the population has a Probability of disease positive test. What is the likelihood 2/1002 = 0.2% that he has the disease tested for? 99% 90% 50% 10% <1% A priori probability A posteriori if test is + 0.002% 50% 98% 0.2% 98% 99.998% Conclusions about Genetic Testing •If a family has several males with ESRD, genetic testing will likely not improve prognostic accuracy. •If the family is very small, the phenotype is likely severe. •Before giving advice that may affect reproductive decisions, consider getting a genetic diagnosis for the prospective parent(s) involved (not just a diagnosis in the family). •Only get a genetic diagnosis if it can change what you will do. •Even very good tests may be misleading if misapplied